| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/15/2001 | WO2001017480A2 Methods and compositions for preventing and treating urinary tract disorders |
| 03/15/2001 | WO2001017479A2 Methods and compositions for preventing and treating prostate disorders |
| 03/15/2001 | WO2001017374A1 Compositions comprising conjugated linoleic acid (cla) |
| 03/15/2001 | WO2001017366A1 Improving condition of elderly pets |
| 03/15/2001 | WO2000064468A3 Therapeutic compositions and methods for enhancing angiogenesis |
| 03/15/2001 | WO2000064418A3 Transdermal therapeutic system with neutralized acrylic adhesive patch |
| 03/15/2001 | WO2000047196A3 Use of statins for treating viral infections |
| 03/15/2001 | WO2000044398A3 Methods for increasing circulating platelets for collection and cryopreservation using thrombopoietin compositions |
| 03/15/2001 | WO2000044358A3 Use of phosphororganic compounds for the prophylactic and therapeutical treatment of infections |
| 03/15/2001 | WO2000041526B1 Use of s-triazines for treating apicomplexan parasitic infections |
| 03/15/2001 | WO2000024419A8 Methods for enhancing wound healing |
| 03/15/2001 | DE19943636A1 Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften Novel dicarboxylic acid derivatives with pharmaceutical properties |
| 03/15/2001 | DE19943635A1 Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften Novel Aminodicarbonsäurederivate with pharmaceutical properties |
| 03/15/2001 | DE19941764A1 Substituierte Acylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikamente oder Diagnostika sowie sie enthaltende Medikamente Substituted acylguanidines, processes for their preparation, their use as medicaments or diagnostics and drugs containing them |
| 03/15/2001 | DE19941217A1 Behandlung der Migräne durch Verabreichung von alpha-Liponsäure oder Derivaten derselben Treatment of migraine by administration of alpha-lipoic acid or derivatives thereof |
| 03/15/2001 | DE19937304A1 Verwendung von CGRP-Antagonisten und CGRP-Release-Hemmern zur Bekämpfung menopausaler Hitzewallungen Use of CGRP antagonists and CGRP release inhibitors to combat menopausal hot flashes |
| 03/15/2001 | DE10027474A1 Synergistic pharmaceutical preparation for treating swelling and inflammation of the nasal mucosa, e.g. due to colds or hay fever, comprising sea water and alpha-sympathomimetic agent |
| 03/15/2001 | CA2388562A1 Mammalian cytokines; related reagents and methods |
| 03/15/2001 | CA2384671A1 Vitronectin receptor antagonists |
| 03/15/2001 | CA2384650A1 Apoptosis proteins |
| 03/15/2001 | CA2384405A1 Dendritic cell membrane protein fire |
| 03/15/2001 | CA2384151A1 Inhibitors of prenyl-protein transferase |
| 03/15/2001 | CA2384101A1 Tyrosine kinase inhibitors |
| 03/15/2001 | CA2384076A1 Novel uses of mammalian ccr6 receptors and related reagents |
| 03/15/2001 | CA2384028A1 Use of conjugated linoleic acid (cla) for the topical treatment of cellulite |
| 03/15/2001 | CA2384006A1 A minimal tau peptide for the nucleation of paired helical filaments |
| 03/15/2001 | CA2383971A1 Prophylactic and therapeutic medicaments for ophthalmic diseases |
| 03/15/2001 | CA2383946A1 Pharmaceutical composition |
| 03/15/2001 | CA2383790A1 Telomere restoration and extension of cell life-span in animals cloned from senescent somatic cells |
| 03/15/2001 | CA2383788A1 Polynucleotides encoding members of the human b lymphocyte activation antigen b7 family and polypeptides encoded thereby |
| 03/15/2001 | CA2383774A1 Fibroblast growth factor-like polypeptides |
| 03/15/2001 | CA2383729A1 Bile acid-substituted phenyl-alkenoylguanidines, method for producing said phenyl-alkenoylguanidines, use thereof as medicaments or diagnostic reagents and medicaments containing the same |
| 03/15/2001 | CA2383186A1 Method to identify gene function using small molecule probes |
| 03/15/2001 | CA2382161A1 Immunoglobulin superfamily polynucleotides, polypeptides, and antibodies |
| 03/14/2001 | EP1082960A2 Use of CRF antagonists and related compositions for treating depression and modifying the circadian rhytm |
| 03/14/2001 | EP1082959A1 NK1 Antagonists for the treatment of depression |
| 03/14/2001 | EP1082875A1 Improved brush block housing for propeller deicing system |
| 03/14/2001 | EP1082456A1 Antisense modulation of cd40 expression |
| 03/14/2001 | EP1082432A2 Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof |
| 03/14/2001 | EP1082426A2 Human socs proteins |
| 03/14/2001 | EP1082419A2 Combination therapy using nucleic acids and conventional drugs |
| 03/14/2001 | EP1082415A1 Methods and compositions useful for modulation of angiogenesis using tyrosine kinase src |
| 03/14/2001 | EP1082345A1 Method of designing agonists and antagonists to egf receptor family |
| 03/14/2001 | EP1082338A1 17 beta-nitro-11 beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties |
| 03/14/2001 | EP1082336A2 Apoptosis modulators that interact with the huntington's disease gene |
| 03/14/2001 | EP1082335A1 Novel secreted and membrane-associated proteins and uses therefor |
| 03/14/2001 | EP1082334A1 Alg-2lp, alg-2 like molecules and uses therefor |
| 03/14/2001 | EP1082314A1 New dipeptidyl peptidase iv effectors |
| 03/14/2001 | EP1082289A1 Methods for identifying novel multimeric agents that modulate receptors |
| 03/14/2001 | EP1082141A1 Cd40 binding molecules and ctl peptides for treating tumors |
| 03/14/2001 | EP1082139A2 CARRIER FOR $i(IN VIVO) DELIVERY OF A THERAPEUTIC AGENT |
| 03/14/2001 | EP1082136A1 The cytokine family member, 2-19 |
| 03/14/2001 | EP1082129A1 Method for the treatment of fertility disorders |
| 03/14/2001 | EP1082126A1 Novel peptides |
| 03/14/2001 | EP1082123A1 Use of a nucleic acid-binding chemotherapeutic agent, and a pharmaceutical composition |
| 03/14/2001 | EP1082113A2 Compositions and methods for alleviating impaired mental function, memory loss and reducing recovery time in anaesthetized mammals |
| 03/14/2001 | EP1082112A1 Endogenous nitric oxide synthesis under conditions of low oxygen tension |
| 03/14/2001 | EP1082106A1 Sublingual buccal effervescent |
| 03/14/2001 | EP1082105A1 Controlled drug delivery system using the conjugation of drug to biodegradable polyester |
| 03/14/2001 | EP1082029A1 Sitostanol formulation with emulsifier to reduce cholesterol absorption |
| 03/14/2001 | EP1005333A4 Methods and compositions for preventing and treating chronological aging in human skin |
| 03/14/2001 | EP0973563A4 System, method and composition for dialysis and shock treatment |
| 03/14/2001 | EP0831817B1 Antigen-processing cell-targeted conjugates comprising a polyamino acid backbone and a non-steroidal anti-inflammatory agent |
| 03/14/2001 | EP0810823B1 Composition for controlling parasites |
| 03/14/2001 | EP0675730B1 Therapeutic combination containing interferon |
| 03/14/2001 | CN1287494A preventives / remedies for glaucoma |
| 03/14/2001 | CN1287492A Method for administering ASPB 28-human insulin |
| 03/14/2001 | CN1287491A Method for administering monomeric insulin analogs |
| 03/14/2001 | CN1287488A Preventives for alcoholic gastritis |
| 03/14/2001 | CN1287485A Dysuria remedies |
| 03/13/2001 | US6201165 Drug screening by contacting isolated cardiomyocyte having calcineurin, calcium calmodulin dependent kinase iv or ii alpha, p38, or mkk6 transgene with compound; measuring physiological parameter; and comparing to control |
| 03/13/2001 | US6201106 Cytokine signal regulators |
| 03/13/2001 | US6201104 Amino acid sequences of angiogenesis-inhibiting protein receptor; drug screening; isolation of angiogenesis related proteins |
| 03/13/2001 | US6201072 Block copolymers of polyether and polyester |
| 03/13/2001 | US6201028 Methods and compositions for prevention and treatment of atherosclerosis and hyperlipidemia with non-steroidal anti-inflammatory drugs |
| 03/13/2001 | US6201014 Unit dosage form of capsaisin or resiniferatoxin in admixture with a carrier for drug delivery to intestines to treat gastrointestinal disorders |
| 03/13/2001 | US6201012 Composition for controlling parasites |
| 03/13/2001 | US6200985 Rapamycin derivatives |
| 03/13/2001 | US6200951 For detecting chitin, binding chitin, and treating fungal infections or for development of products useful for fungal infection therapy |
| 03/13/2001 | US6200787 Phenylalanyl tRNA synthetase polypeptides from streptococcus pneumoniae |
| 03/13/2001 | US6200780 Human interferon-ε(IFN-ε), a type I interferon |
| 03/13/2001 | US6200777 Human p101 polynucleotides |
| 03/13/2001 | US6200776 Polynucleotides encoding human sodium bicarbonate cotransporters |
| 03/13/2001 | US6200746 Detection of enzyme inhibitor; evaluate kinase phosphorylation in presence and absence of virus, incubate with test compound, monitor decrease in enzyme activity |
| 03/13/2001 | US6200604 Sublingual buccal effervescent |
| 03/13/2001 | US6200599 Ortho ester lipids |
| 03/13/2001 | US6200598 Active materials entrapped within liposome interior |
| 03/13/2001 | US6200593 Contraceptive method employing buccal delivery of steroidal active agents |
| 03/13/2001 | US6200567 An antibody that binds to the common beta c chain of the receptor for gm-csf, il-3 and il-5 |
| 03/13/2001 | US6200556 Indigestible dietary composition orally administered to the gastrointestinal canal which is functional to progressively hydrate therethrough; mixture of edible alkyl cellulose compound and an edible sorbitol or glycerol |
| 03/13/2001 | US6200549 Contains less than 0.0001% w/w surfactant based upon the weight of medicament |
| 03/08/2001 | WO2001017211A2 Communications system |
| 03/08/2001 | WO2001016604A1 Screening for agents modulating tgf-beta cell signaling |
| 03/08/2001 | WO2001016603A2 Analysis and treatment of body weight and eating disorders |
| 03/08/2001 | WO2001016377A2 Diagnostics and therapeutics for osteoporosis |
| 03/08/2001 | WO2001016358A2 Method of screening for triacyglycerol hydrolase inhibitors |
| 03/08/2001 | WO2001016331A1 Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression |
| 03/08/2001 | WO2001016322A2 Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| 03/08/2001 | WO2001016319A2 Compositions and methods for the treatment of immune related diseases |
| 03/08/2001 | WO2001016304A2 Genetically engineered cell lines, and their uses, in particular for neurotoxicity testing |